Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31
Dow Jones2026/08/03 21:37Novartis's Pluvicto was approved by the Food and Drug Administration for use in combination with an androgen receptor pathway inhibitor. "Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto," at 5:06 p.m. ET on July 31, incorrectly said Pluvicto was approved for use in combination with an androgen receptor pathway inhibitor and androgen deprivation therapy.
(END) Dow Jones Newswires
August 03, 2026 17:37 ET (21:37 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ – Gold mining stocks rise as gold price rebounds from sell-off
Australian Dollar seen vulnerable after weak data – Societe Generale
Gold Price Forecast: XAU/USD rallies remain limited with bulls capped below $4,050
Crypto prices
More
